Neuroendocrine tumours
Short acting.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Initially 50micrograms once or twice daily, gradually increased according to response to 200micrograms three times daily.
Long acting. Prescribe as the IPSEN brand.
Maximum dose 120mg every 28 days. If there are active symptoms despite the maximal dose, the frequency may be increased to every 21 days under specialist advice (off-label).
Maximum dose 120mg every 28 days. If there are active symptoms despite maximal dose, the frequency may be increased to every 21 days under specialist advice (off-label).
Maximum dose 120mg every 28 days. If there are active symptoms despite the maximal dose, the frequency may be increased to every 21 days under specialist advice (off-label).
Long acting.
By deep intramuscular injection using depot injection, 20mg every 4 weeks, to be administered into the gluteal muscle. If subcutaneous octreotide has been commenced first this should be continued for 2 weeks after first dose of depot octreotide. If there are active symptoms despite the maximal dose, the frequency may be increased to every 3 weeks under specialist advice (off-label).
By deep intramuscular injection using depot injection, 20mg every 4 weeks, to be administered into the gluteal muscle. If subcutaneous octreotide has been commenced first this should be continued for 2 weeks after first dose of depot octreotide. If there are active symptoms despite the maximal dose, the frequency may be increased to every 3 weeks under specialist advice (off-label).
By deep intramuscular injection using depot injection, 20mg every 4 weeks, to be administered into the gluteal muscle. If subcutaneous octreotide has been commenced first this should be continued for 2 weeks after first dose of depot octreotide. If there are active symptoms despite the maximal dose, the frequency may be increased to every 3 weeks under specialist advice (off-label).
Refer to product literature.
Refer to product literature.
Refer to product literature.
Prescribing Notes:
- Somatostatin analogues are used for the relief of symptoms associated with neuroendocrine tumours, particularly carcinoid syndrome. They also have anti-tumour effects and can slow disease progression and rarely reduce tumour bulk.
- Although in the past most patients were commenced on short acting octreotide prior to the commencement of long acting somatostatin analogues, the majority of patients are now commenced directly on the long acting analogues.
- Treatment may cause diarrhoea due to exocrine pancreatic insufficiency.
- Somatostatin analogues for neuroendocrine tumours and acromegalic patients are appropriate for shared care arrangements to facilitate the seamless transfer of individual patient care from secondary care to general practice.
History Notes
28/03/2024
Lantreotide product update, ERWG March 24.
11/05/2023
Somatuline LA 30mg powder and solvent for suspension for injection vials removed as discontinued.
21/02/2023
Addition of alternative long-acting octreotide formulation, ERWG Jan 23.
16/02/2022
East Region Formulary content agreed.